Table 2.2: Anti-Viral Vero Cell-Based Vaccines
Figure 1.1: Overall Decline in Worldwide Death Rates
Figure 2.5: Application of Nano-Sized Delivery Systems
Figure 5.11: Emergent’s ADAPTIR Design Technology for Antibody Therapeutics
Figure 5.15: Genocea Technology for Screening Candidate Vaccines Components
Figure 6.2: Development of Anti-cancer Vaccine Products and the Regulatory Guidance Throughout the Process
Figure 8.1: Makeup of the Participants in the Survey
Figure 8.2: Breakdown of Opinions of the Industrial Commitment of Resources
Figure 8.3: How Should the Industry Focus its R&D Efforts in Vaccine Technology?
Figure 8.4: What are the Most Promising Cancer Vaccine Targets?
Figure 8.5: How Seriously are the Federal Governmental Bodies Committed to Vaccine Technology?
Figure 8.6: State and Local Governmental Support for R&D. How Does it Stack Up?
Figure 8.7: The Softest Cancer Vaccine Target
Figure 8.8: Where is the Vaccine Market Headed?
Figure 8.9: Why Would a Vaccine Development Program be Vetoed?
Figure 8.10: The Fallout from Vaccine Denialism
Figure 8.11: Where is Bioprocessing of Vaccines Headed?
Figure 8.12: Cancer Vaccines: Still a Long Ways Off
Figure 8.13: AIDS Vaccines: Further Down the Road than Cancer Vaccines?
Figure 8.14: The Road Ahead: Daunting Challenges
Figure 8.15: Is Regulatory Control of Vaccines a Problem?
Figure 8.16: How Does the Industry Feel About Vaccines as a Barrier to Terroristic Threats?
Figure 8.17: When Vaccines Fail
Figure 8.18: Bioinformatics: A Pathway to Innovative Vaccine Antigens
Figure 8.19: Counteracting Vaccine Denialism
Figure 8.20: Opinions on the Rise of Therapeutic Vaccines
Figure 8.21: The Future of Oral Vaccines
Figure 8.22: Vaccine Technology in the Third World
Figure 8.23: Vaccines and the Battle Against Hepatitis C
Figure 8.24: Academic/Industrial Partnerships: Do They Have a Future?
Figure 8.25: Alternative Pathways Toward Speeding Vaccine Development
Figure 8.26: A New Look at DNA Vaccines